FAM
TRIL

Fred Alger Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Fred Alger Management’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-26,200
Closed -$385K – 525
2020
Q4 		$385K Sell
26,200
-590
-2% -$8.51K ﹤0.01% 412
2020
Q3 		$381K Sell
26,790
-23,210
-46% -$231K ﹤0.01% 392
2020
Q2 		$405K Buy
50,000
+10,000
+25% +$61.9K ﹤0.01% 409
2020
Q1 		$162K Buy
+40,000
New +$151K ﹤0.01% 402
2016
Q4 		– Sell
-23,000
Closed -$340K – 538
2016
Q3 		$340K Buy
+23,000
New +$265K ﹤0.01% 367

Other funds holding TRIL

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Fred Alger Management's TRIL Position: Q1 2021 in Review

Fred Alger Management sold out of Trillium Therapeutics Inc. (TRIL) in Q1 2021, closing a stake of 26,200 shares — an estimated $385K sold.

Fred Alger Management first reported a position in TRIL in Q3 2016 and held it in 5 quarters. The position peaked at $405K in Q2 2020. 125 funds tracked by Wall St. Rank hold TRIL as of Q1 2021.

  • Fred Alger Management reported no remaining Trillium Therapeutics Inc. position as of Q1 2021 after selling out during the quarter.
  • Fred Alger Management sold 26,200 Trillium Therapeutics Inc. shares in Q1 2021, an estimated $385K.
  • Fred Alger Management first reported a position in Trillium Therapeutics Inc. in Q3 2016 and held it in 5 quarters.
  • Fred Alger Management's Trillium Therapeutics Inc. position peaked at $405K in Q2 2020.
  • 125 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q1 2021.

Based on Fred Alger Management's 13F filing for Q1 2021, filed 17 May 2021.